Julia Haller Biography and Net Worth

Director of Bristol Myers Squibb

Dr. Haller has served since 2007 as ophthalmologist-in-chief of Wills Eye Hospital in Philadelphia, PA, where she holds the William Tasman, MD endowed chair. She is professor and chair of the department of ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals.

A magna cum laude graduate of Princeton, Dr. Haller received her MD degree from Harvard Medical School. She trained at the Wilmer Eye Institute at Johns Hopkins where she served as the first female chief resident. She then joined the Johns Hopkins faculty, where she held the Katharine Graham Chair in Ophthalmology before her move to lead Wills.

One of the world's most renowned retina surgeons, Dr. Haller has innovated translational advances against blindness on many fronts, including sustained drug delivery devices, ocular pharmacotherapy, retinal "chip" implants, gene therapy, telemedicine and combating health care disparities. Elected to the National Academy of Medicine where she chairs Section 6, she has held many leadership roles in medicine and her community. She is president of the American Ophthalmological Society, chair of the Heed Ophthalmic Foundation Board, vice president of the Ophthalmology Foundation and president of the Macula Society. Dr. Haller also serves on the Executive Committee of the Board of the Philadelphia Orchestra and is a trustee emerita of Princeton University.

Dr. Haller is a former director of Eyenovia, Inc., Opthea Limited and Outlook Therapeutics, Inc.

What is Julia A. Haller's net worth?: The estimated net worth of Julia A. Haller is at least $1.88 million as of November 5th, 2026. Dr. Haller owns 30,279 shares of Bristol Myers Squibb stock worth more than $1,882,203 as of November 10th. This net worth approximation does not reflect any other assets that Dr. Haller may own. Learn More about Julia A. Haller's net worth.
How do I contact Julia A. Haller?: The corporate mailing address for Dr. Haller and other Bristol Myers Squibb executives is Route 206 And Province Line Road, Princeton, NJ, 08543. Bristol Myers Squibb can also be reached via phone at (609) 252-4621 and via email at [email protected]. Learn More on Julia A. Haller's contact information.
Has Julia A. Haller been buying or selling shares of Bristol Myers Squibb?: During the past quarter, Julia A. Haller has sold $240,578.00 in shares of Bristol Myers Squibb stock. Most recently, Julia A. Haller sold 3,800 shares of the business's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a transaction totalling $240,578.00. Following the completion of the sale, the director now directly owns 30,279 shares of the company's stock, valued at $1,916,963.49. Learn More on Julia A. Haller's trading history.
Who are Bristol Myers Squibb's active insiders?: Bristol Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Julia Haller (Director), Benjamin Hickey (President, RayzeBio), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Wendy Short Bartie (Executive Vice President, Corporate Affairs), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol Myers Squibb?: During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 34,300 shares worth more than $2,124,428.00. The most recent insider tranaction occured on November, 5th when Director Julia A. Haller sold 3,800 shares worth more than $240,578.00. Insiders at Bristol Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol Myers Squibb.
Information on this page was last updated on 11/5/2026.

Julia A. Haller Insider Trading History at Bristol Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/5/2026	Sell	3,800	$63.31	$240,578.00	30,279

Julia A. Haller Buying and Selling Activity at Bristol Myers Squibb

Bristol Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $62.16

$61.80

$63.06

50 Day Range

MA: $62.25

$56.73

$68.06

2 Week Range

Now: $62.16

$45.26

$68.64

Volume

7,667,769 shs

Average Volume

12,328,546 shs

Market Capitalization

$127.06 billion

P/E Ratio

13.78

Dividend Yield

3.93%

Beta

0.2